Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer

Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer

Accepted Manuscript Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer R.Mic...

2MB Sizes 12 Downloads 102 Views

Accepted Manuscript Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer R.Michael Tuttle, MD, Marcia S. Brose, MD, PhD, Enrique Grande, MD, Sun Wook Kim, MD, Makoto Tahara, MD, Mona M. Sabra, MD PII:

S1521-690X(17)30042-8

DOI:

10.1016/j.beem.2017.04.014

Reference:

YBEEM 1155

To appear in:

Best Practice & Research Clinical Endocrinology & Metabolism

Please cite this article as: Tuttle RM, Brose MS, Grande E, Kim SW, Tahara M, Sabra MM, Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer, Best Practice & Research Clinical Endocrinology & Metabolism (2017), doi: 10.1016/ j.beem.2017.04.014. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine

2

refractory differentiated thyroid cancer

RI PT

1

R Michael Tuttle, MD,1 Marcia S. Brose, MD, PhD,2 Enrique Grande, MD,3 Sun Wook Kim,

4

MD,4 Makoto Tahara, MD,5 Mona M. Sabra, MD1

5

1

Endocrinology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;

6

2

Department of Otorhinolaryngology: Head and Neck Surgery, Abramson Cancer Center of the

7

University of Pennsylvania, Philadelphia, PA, USA; 3Medical Oncology Department, Ramón y

8

Cajal University Hospital, Madrid, Spain; 4Division of Endocrinology and Metabolism,

9

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of

M AN U

SC

3

10

Medicine, Seoul, Korea; 5Department of Head and Neck Medical Oncology, National Cancer

11

Center Hospital East, Kashiwa, Chiba, Japan

12

Author Contact Information:

14

R Michael Tuttle

15

Endocrinology Service, Department of Medicine

16

Memorial Sloan Kettering Cancer Center,

17

New York, NY, USA

18

Email: [email protected]

TE

EP

AC C

19

D

13

20

Marcia S. Brose

21

Director, Center for Rare Cancers and Personalized Therapy

22

Abramson Cancer Center

23

Associate Professor

24

Department of Otorhinolaryngology: Head and Neck Surgery,

25

Department of Medicine, Division of Hematology and Oncology,

26

University of Pennsylvania, Perelman School of Medicine,

27

Philadelphia, PA, USA

28

Phone: 1-215-746-7344; Fax: 1-215-8982136; Email: [email protected]

1

ACCEPTED MANUSCRIPT

29

Enrique Grande

31

Servicio de Oncología Médica,

32

Hospital Universitario Ramón y Cajal de Madrid,

33

28034-Madrid, SpainPhone: +34913368263; Fax: +34913369181; Email:

34

[email protected]

RI PT

30

35

SC

36

Sun Wook Kim

38

Professor

39

Thyroid Center

40

Division of Endocrinology and Metabolism,

41

Samsung Medical Center

42

Sungkyunkwan University School of Medicine, Seoul, Korea

43

Phone: +82-2-3410-1653; Fax: +82-2-6918-4653; Email: [email protected]

D

44

M AN U

37

Makoto Tahara

46

Chief, Department of Head and Neck Medical Oncology,

47

National Cancer Center hospital East

48

6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan

49

Phone: +81-47133-1111; Fax: +81-4734-6957; Email: [email protected]

EP

AC C

50

TE

45

51

Mona M. Sabra

52

Endocrinology Service, Department of Medicine,

53

Memorial Sloan Kettering Cancer Center,

54

New York, NY, USA.

55

Email: [email protected]

56 57

2

ACCEPTED MANUSCRIPT

ABSTRACT

59

Multitargeted kinase inhibitors have been shown to improve progression-free survival in patients

60

with structurally progressive, radioactive-iodine refractory differentiated thyroid cancer. While

61

the inclusion criteria for phase 3 clinical trials and clinical practice guidelines provide guidance

62

with regard to the minimal requirements that need to be met prior to initiation of a multitargeted

63

kinase inhibitor, a better way to integrate the rate of structural disease progression with the size

64

of the metastatic foci to more precisely define the optimal time to recommend initiation of

65

therapy for individual patients is needed.

66

assessments of tumor size and growth rates (structural disease doubling times) to define the

67

critical point in time when the volume and rate of progression of metastatic structural disease

68

merits consideration for initiation of systemic therapy (the inflection point).

69 70

Keywords: inflection point, doubling time, growth curves, thyroid cancer

SC

RI PT

58

AC C

EP

TE

D

M AN U

In this manuscript we describe how to use

3

ACCEPTED MANUSCRIPT

Introduction

72

A structural incomplete response to initial therapy (persistent or recurrent structural disease) is

73

seen in up to 30% of patients with differentiated thyroid cancer who have been treated with total

74

thyroidectomy and radioactive-iodine (RAI) remnant ablation (1-3). While the majority of

75

structural incomplete responses will have persistent disease only in the neck, as many as 5% to

76

10% may have distant metastasis at presentation, with an additional 5% to 10% developing

77

distant metastases during follow-up (4). The majority of distant metastases are located in the

78

lungs, with a smaller number located in the bones or in other sites (4). While many distant

79

metastases remain asymptomatic, disease progression can be associated with a wide variety of

80

symptoms, including pain and dyspnea on exertion.

SC

M AN U

81

RI PT

71

Although two-thirds of patients with metastatic disease demonstrate substantial uptake of RAI, only 42% demonstrate complete structural resolution of their disease, and fewer than 10%

83

demonstrate complete resolution of both biochemical and structural evidence of disease (5-7).

84

While 10-year survival rates of > 95% have been documented in young patients with distant

85

metastases, a median 10-year overall survival rate of < 50% can be expected in older patients

86

with either papillary or follicular thyroid cancer presenting with distant metastases (8, 9).

87

Unfortunately, long-term overall survival drops to 10% when distant metastases are not

88

responsive to RAI therapy (5). Further, overall survival is significantly worse in patients with

89

bone or brain metastases (6, 10). While traditional chemotherapy is associated with short-term

90

response rates of ≤ 25% (11), multitargeted kinase inhibitors have demonstrated much better

91

results with documented improvements in progression-free survival associated with a tolerable

92

side-effect profile (12-15).

AC C

EP

TE

D

82

4

ACCEPTED MANUSCRIPT

93

In a recently described cohort of 199 patients with pulmonary metastases, an increase in the size and/or number of metastatic foci was documented by Sabra and colleagues in 68% of

95

patients despite repeated doses of RAI therapy (Figure 1) (6). For the entire cohort, the median

96

time to progression was 3.7 years, with 17 % of patients progressing by the end of year 1, 35%

97

by year 2, 55% by year 5, and 65% by year 10. However, disease progression occurred sooner

98

and more often in RAI refractory patients (Table 1). Further, progression-free survival was

99

significantly worse in patients with aggressive histologies (poorly differentiated thyroid cancer,

SC

RI PT

94

hurthle cell cancer), fluorodeoxyglucose-positron emission tomography (FDG-PET) avid disease,

101

metastatic lesions > 1 cm in diameter, bone metastasis, and in patients over 45 years of age at the

102

time the metastatic disease was identified (6).

M AN U

100

With the approval of two oral multitargeted kinase inhibitors (lenvatinib and sorafenib)

104

for the treatment of RAI refractory thyroid cancer, the clinician and the patients are now faced

105

with the challenging decision of when to initiate multitargeted kinase inhibitor therapy. Both

106

agents are approved for progressive or symptomatic RAI refractory thyroid cancer that is not

107

amenable to localized therapies. However, in clinical practice, it is quite common to see patients

108

with RAI refractory disease that is either stable or slowly progressive. Further, in some patients,

109

the pace of clinical disease progression appears to increase as the metastatic lesions increase in

110

size. Therefore, the precise time point in the clinical course of disease progression to initiate

111

therapy for an individual patient can be difficult to identify. As such, treatment of advanced

112

thyroid cancer is optimally undertaken in the context of a functional, integrated, disease-

113

management team because management of these patients may require extensive surgery, external

114

beam irradiation, radiofrequency ablation, embolization, or metastasectomy either in addition to

115

or prior to starting other multitargeted kinase inhibitor therapies (16). Because oncologists and

AC C

EP

TE

D

103

5

ACCEPTED MANUSCRIPT

other specialists that give multitargeted inhibitors often will need to educate and establish a

117

relationship with the patient prior to the initiation of treatment, the discussion below should be

118

used to help all health care providers in anticipating when a patient may be approaching the need

119

for multitargeted inhibitors and initiate timely referrals to the treating physicians.

RI PT

116

120

Examining the time course of disease progression in individual patients with distant metastases

122

In clinical practice, it is very apparent that the rate of disease progression and the

M AN U

SC

121

likelihood that the metastatic disease will become life-threatening varies dramatically among

124

individual patients with distant metastases. Several of the common patterns of disease

125

progression are presented in Figure 2 where the volume of disease is plotted along the y-axis and

126

the time from diagnosis presented along the x-axis. In this theoretical figure, patients

127

demonstrating more rapid disease progression over time (Figure 2 curves A, B and C) can be

128

expected to reach a lethal tumor burden more quickly than patients with slowly growing (Figure

129

2 curve D) or stable disease (Figure 2 curves E and F).

TE

EP

130

D

123

The biological basis for these theoretical volume of disease curves is the long-standing observation that human malignant tumors demonstrate a pattern of exponential growth

132

(1248163262128 cells) that remains remarkably constant over time until large

133

burdens of disease are achieved (17-19). It is important to remember that, because tumor growth

134

is exponential, relatively small changes in tumor diameter are associated with much larger

135

changes in tumor volume that often become clinically more problematic as the tumors exceed 1

136

cm in diameter (Figure 3). Because of their near constant exponential growth pattern, the time

137

required for a tumor to increase in diameter from 0.5 to 8 cm across a spectrum of doubling

138

times can be demonstrated by graphing the diameter of the largest metastatic foci (in

AC C

131

6

ACCEPTED MANUSCRIPT

centimeters) versus follow-up time in years (Figure 4A). To facilitate the use of the growth

140

curves as predictors of outcomes in clinical practice, it is easier to visualize exponential doubling

141

time curves as straight lines by expressing them as semilog plots where the diameter is presented

142

on a logarithmic scale on the y-axis with time on the standard x-axis linear scale (Figure 4B).

143

The semilog curves make it easier to predict tumor diameters that can be expected in the future

144

once the diameter doubling time has been established for particular metastatic foci.

SC

RI PT

139

While the figures and tables in this manuscript largely describe doubling times in terms

146

of change in diameter of individual metastatic lesions, it is important to note that eligibility for

147

clinical trials allows for measurement of up to 5 metastatic foci in different organ locations, with

148

preference given to the lesions with the greatest diameter that can be reproducibly measured with

149

accuracy. Because of the potential for heterogeneity of growth rates among metastatic foci, it is

150

likely that a doubling time calculated using the sum of diameters of multiple metastatic foci may

151

more accurately reflect the clinical course of the disease than measurements of individual lesions.

152

Identifying the clinical inflection point

D

TE

EP

153

M AN U

145

Rather than using “inflection point” in a strictly mathematical sense (the precise point at which a curve changes from convex to concave or vice versa), we are using the term in more of a

155

general sense to designate a turning point or significant change in the clinical situation. From a

156

clinical perspective, crossing over the 1-cm diameter threshold is an important boundary and

157

represented the minimum size required for participation in most prospective therapeutic clinical

158

trials. Even though the tumor size doubling time is constant as tumors increase in size, the

159

clinical impact of increasing tumor diameter becomes much more significant as the tumor

160

diameter exceeds 1 cm (See Figure 3). For tumor diameters < 1 cm, biomarker doubling times

AC C

154

7

ACCEPTED MANUSCRIPT

161

may provide a reliable estimate of tumor growth prior to the time when the volume of disease is

162

large enough to be reliably measured with cross-sectional imaging (18, 20-22). The rapidity with which a tumor passes through the inflection point is dependent on the

RI PT

163

doubling time, with a far quicker transition in tumors demonstrating a 6-month diameter

165

doubling time (6–12 months) compared with tumors demonstrating a 2 year diameter doubling

166

time (2–4 years). Therefore, we picture the inflection point as a region on the growth curves that

167

integrates both volume of disease and tumor growth rates (doubling times) as depicted by the

168

grey triangle on Figure 4B.

M AN U

169

SC

164

As illustrated in Figures 4A and 4B, the rate of disease progression (represented by the slope of the line or the actual doubling time ) will be the primary determinant in the development

171

of a life-threatening mass of metastatic disease (18). If a treatment (or combination of

172

treatments) significantly decreases the volume of disease and the growth rate remains stable, one

173

could reasonably expect improved clinical outcomes even though asymptomatic small volume

174

disease may continue to progress and eventually become clinically apparent at a time predicted

175

by the underlying tumor doubling time. However, in the case of multitargeted kinase inhibitor

176

treatments that decrease the growth rate (and prolong the diameter doubling time), it is possible

177

that the time to the development of a lethal tumor mass may be delayed by months to years.

TE

EP

AC C

178

D

170

As previously noted, the rate of change in either the tumor biomarkers or structurally

179

evident disease usually remains quite constant over time in the absence of multitargeted kinase

180

inhibitor therapies that might affect the secretion of these biomarkers (18-22). However,

181

occasionally, the rate of disease progression will dramatically increase such that the rate of

182

growth departs from the original predicted slope. In these cases, additional mutations acquired

183

during follow up, or alternatively, upregulation of an already active pathway, may provide a

8

ACCEPTED MANUSCRIPT

growth advantage to a subclone of the thyroid cancer. This may occur in the case of the

185

development of a new site of disease and is not accounted for in the above models. This subclone

186

may define a new more rapid growth rate (and hence a new slope and doubling time) and is often

187

associated with de-differentiation of the tumor histology and a shift toward markedly FDG PET

188

avid disease (23). If a solitary site of disease such as this develops in the setting of slower

189

growing disease, local therapy might be considered to restore the previously slower growth rate

190

and allow a longer period prior to initiation of multitargeted kinase inhibitor therapy. Still, the

191

vast majority of disease progression follows the initially predicted biochemical and structural

192

growth curves for many years after diagnosis (18, 20-22, 24).

M AN U

SC

RI PT

184

193

Guidance from phase 3 trial entry criteria and cancer-management guidelines regarding

195

initiation of multitargeted kinase inhibitor therapy in RAI refractory disease

TE

D

194

Inclusion criteria for the prospective, randomized, registration trials for sorafenib and

197

lenvatinib required an increase of ≥ 20% in the sum of the longest diameters of target lesions

198

defined by Response Evaluation Criteria in Solid Tumors (RECIST) over either a 13-month

199

(lenvatinib) or 14-month (sorafenib) period (12, 15) or the identification of a new lesion. Based

200

primarily on expert opinion, the 2015 American Thyroid Association thyroid cancer-

201

management guidelines suggested that a 20% increase over a 6-month period should prompt

202

consideration of multitargeted kinase inhibitor therapies (25). Similarly, a group of thyroid

203

cancer experts also recommend using a minimum tumor volume (> 1 cm) with structural disease

204

progression as defined by RECIST progression over < 12-14 months to define the time point to

205

initiate systemic therapy in radioactive iodine refractory thyroid cancer (26). The National

206

Comprehensive Cancer Network guidelines noted that the “pace of disease progression should be

AC C

EP

196

9

ACCEPTED MANUSCRIPT factored into treatment decisions” without defining a tumor size or rate of change that should

208

prompt initiation of kinase inhibitor therapy in patients with RAI refractory differentiated thyroid

209

cancer or medullary thyroid cancer (27). While RECIST evaluations are the primary tool for

210

evaluating changes in disease status in clinical trials, they are not used in clinical practice and

211

can be a challenge to apply retrospectively. Therefore, we sought an alternative way to describe

212

tumor growth rates that would be more accessible and understandable to clinicians and patients.

213

Table 2 shows the relationship between the percentage increase per year in tumor

214

diameter, which form the basis for current recommendations regarding initiation of multitargeted

215

kinase inhibitor therapy, and tumor diameter doubling times for a hypothetical metastatic foci

216

measured as 1 cm in maximal diameter at baseline. A 20% increase in metastatic foci diameter

217

over a 12 to 14-month period would approximate a doubling time of 4 years. A 20% increase in

218

tumor diameters over a 6-month period would correlate with a diameter doubling time of

219

approximately 2 years (≈ 40% growth over 1 year).

SC

M AN U

D

TE

Based on these publications (12, 15, 25), distant metastatic lesions greater than 1 cm

EP

220

RI PT

207

demonstrating a maximum diameter doubling time of < 2–4 years would meet the criteria for

222

consideration for multitargeted kinase inhibitor therapy. Asymptomatic metastatic lesions in

223

noncritical locations with tumor diameter doubling times longer than 4 years could be considered

224

for active surveillance.

225 226 227 228

AC C

221

A practical approach to using growth rates and the inflection point to guide clinical management An individualized assessment of the rate of structural disease progression is the cornerstone of critical decision-making in patients with advanced metastatic thyroid cancer. In its

10

ACCEPTED MANUSCRIPT

simplest form, patients with slow disease progression, manifest by longer tumor doubling times,

230

can be followed with less frequent cross-sectional imaging and less aggressive treatment

231

interventions than patients demonstrating more rapid structural disease progression. Tumor

232

volume doubling times can be calculated using freely available online calculators from either the

233

American Thyroid Association (http://www.thyroid.org/professionals/calculators/thyroid-with-

234

nodules/) or from the Kuma Hospital (http://www.kuma-h.or.jp/english/about/doubling-time-

235

progression-calculator/) web sites. When evaluating patients with thyroid cancer with

236

structurally identifiable distant metastases, we find that the answers to 4 critical questions can

237

provide valuable insights that can guide optimal management recommendations (Figure 5):

M AN U

SC

RI PT

229

238

1. Are the metastatic lesions RAI refractory?

239

2. Is the patient symptomatic or at risk for developing symptoms because of the location of

D

disease?

TE

240

3. Is the rate of structural disease progression established?

242

4. Has the tumor reached the 1- to 2-cm inflection point?

After determining whether the metastatic lesions are RAI avid and assessing the presence

AC C

243

EP

241

244

or likelihood of rapidly developing clinical symptoms, the key factors that guide the proper

245

timing for initiation of other multitargeted kinase inhibitor therapies include tumor size and the

246

rate of structural disease progression. Because the inflection-point concept integrates both tumor

247

doubling time and volume of disease estimates, it can be used to guide decision- making with

248

regard to when it would be appropriate to consider initiation of multitargeted kinase inhibitor

249

therapy.

11

ACCEPTED MANUSCRIPT

250

Crossing the inflection point at approximately 1 cm in diameter is a minimal requirement for consideration of multitargeted kinase inhibitor therapies, based on the two phase 3 trials that

252

have been completed. In our opinion, while patients with very rapid diameter doubling times (< 1

253

year) should be considered for multitargeted kinase inhibitor therapy as their tumors approach 1

254

cm in diameter, patients with longer doubling times (1–4 years) may not require initiation of

255

therapy until tumors are in the 1.5- to 2-cm range depending on overall tumor volume, symptoms,

256

location of disease and patient preference (Table 3). Graphically, the threshold to consider

257

initiation of multitargeted kinase inhibitor therapy within each of the established diameter

258

doubling time growth curves is depicted by a grey triangle in Figure 4B.

SC

M AN U

259

RI PT

251

Tumors with even longer doubling times (> 4 years) may not require multitargeted kinase inhibitor therapy for some time depending on the starting tumor volumes. In our view, though

261

they are at risk for continued disease progression, asymptomatic patients with longer doubling

262

times and subcentimeter metastases that have not passed through the inflection point should

263

generally be followed with close observation. Active surveillance can allow these patients a

264

prolonged period of symptom-free living without the side effects of the multitargeted kinase

265

inhibitor therapies and, thus, can be pursued in these cases. Our recommended approach is,

266

therefore, observation with serial imaging in the vast majority of asymptomatic patients with

267

metastatic lesions demonstrating a doubling time greater than 4 years.

TE

EP

AC C

268

D

260

Thus multitargeted kinase inhibitor therapy would be considered: (1) at the 1- to 2-cm

269

inflection point, or possibly earlier, in patients with RAI refractory disease with doubling times

270

< 2–4 years or (2) after passing through the inflection point, if ever, in patients with stable or

271

very slowly progressive disease (doubling times > 4 years). It is important to emphasize that

272

therapeutic interventions should be initiated without regard to the inflection point if the patient

12

ACCEPTED MANUSCRIPT

has (1) tumor associated symptoms such as dyspnea on exertion and cachexia, (2) lytic bone

274

metastases that may benefit from bisphosphonate or rank ligand inhibitor therapy, (3) metastatic

275

disease likely to cause local symptoms that can be treated with a directed therapy such as

276

surgical resection, EBRT, embolization, or radiofrequency ablation, or (4) patients with a very

277

high overall tumor volume despite smaller sized lesions (e.g. multiple lesions that may only have

278

a maximal tumor volume of 1 cm, but overall due to high number represent a greater risk of

279

symptomatic progression).

SC

In metastatic disease that continues to be responsive to radioactive iodine administration,

M AN U

280

RI PT

273

progression through the 1- to 2-cm inflection point is not a requirement for additional RAI

282

therapies as these treatments work best in low volume (5). Continued decrease in tumor volume

283

in response to previous treatments may prompt additional RAI treatments depending on the age

284

of the patient, the volume of residual disease, the rate of disease progression, the cumulative

285

administered activity of RAI, side-effect profile for individual patients, and patient desires/goals.

286

However, because fewer than 10% of RAI avid patients will achieve complete remission,

287

observation is usually recommended for patients with persistent, stable small-volume disease or

288

patients with only biochemical evidence of persistent disease (6).

TE

EP

AC C

289

D

281

In addition to using the doubling time curves as one of the key indicators for initiation of

290

multitargeted kinase inhibitor therapy, they can also be used to evaluate the efficacy (or failure)

291

of ongoing treatments. Traditionally, a multitargeted inhibitor is discontinued once the patient

292

documents clinically significant structural disease progression, which may be required as part of

293

the clinical trial design. However, we would argue that an agent may still be having a clinically

294

significant effect if treatment is associated with a clinically significant increase in doubling time,

295

even if structural disease progression eventually develops. Rather than using disease stability as

13

ACCEPTED MANUSCRIPT

the only indicator of treatment success, a paradigm that emphasizes the impact of drug treatment

297

on increasing the doubling time would identify patients in whom even slowly growing disease

298

would still be considered evidence of treatment efficacy if the doubling rate has been decreased

299

enough to predict a likely improvement in progression-free survival or overall survival. In this

300

approach, a switch to another agent would be delayed until there was evidence not only of

301

disease progression, but progression with a rapid doubling time indicative of a lack of efficacy of

302

the current drug. Using this approach, tumor doubling time could be used to evaluate both the

303

appropriateness of initiating multitargeted kinase inhibitor therapy and the interpretation of the

304

efficacy of ongoing therapy.

305

Summary

SC

M AN U

306

RI PT

296

Optimal management of patients with metastatic differentiated thyroid cancer requires careful consideration of multiple tumor-associated and patient-related factors within the context

308

of an experienced multidisciplinary team. Because our current multitargeted kinase inhibitor

309

therapy options are seldom curative, either in the RAI refractory or RAI responsive disease

310

setting, proper selection of patients for intervention with treatment options that are either

311

palliative or designed to slow disease progression is critical. Optimal decision-making with

312

regard to when to initiate multitargeted kinase inhibitor therapy in the metastatic disease setting

313

requires the clinician and the patient to thoughtfully integrate an understanding of the patient’s

314

symptom burden, tumor progression, and potential tolerance of treatment-related side effects.

AC C

EP

TE

D

307

315

14

ACCEPTED MANUSCRIPT

316 317

Practice Points 

Multi-targeted kinase inhibitors have demonstrated improvement in progression free survival in patients with structurally progressive, radioactive iodine refractory thyroid

319

cancer. 

321

mortality in radioactive iodine refractory thyroid cancer. 

323 324

SC

322

Tumor burden, location and growth rates are the primary determinates of morbidity and

Increases in tumor size are remarkably consistent over time and follow classical

M AN U

320

RI PT

318

exponential growth curves with distinct structural doubling times. 

Relatively small increases in tumor diameter are associated with much larger increases in

325

tumor volume which often becomes clinically significant as the tumor diameter exceeds 1

326

cm. 

By integrating tumor size (maximal diameter) with the rate of structural disease

D

327

progression (tumor diameter doubling times), it is possible to identify a period of time

329

(the inflection point) where the structural disease progression is becoming clinically

330

significant.

332 333 334

EP



The inflection point should identify the earliest time point that consideration should be

AC C

331

TE

328

given for the initiation of multi-targeted kinase inhibitors in otherwise asymptomatic patients.



Prolongation of structural disease doubling time, even if associated with slow disease

335

progression, would demonstrate a favorable therapeutic effect of multi-targeted kinase

336

inhibitor therapy.

337 338

15

ACCEPTED MANUSCRIPT

339

341

Research Agenda 

342

Trials are needed that specifically examine the effectiveness of multi-targeted kinase inhibitors based on tumor size and structural disease doubling times.



Trials are needed to determine if initiating multi-targeted kinase inhibitors at the time

SC

343

RI PT

340

of clinically significant disease progression (the inflection point) is better or worse

345

than starting treatment either before or after that time point.

346



M AN U

344

Further research is needed to determine if improvements in structural disease

347

doubling times, despite some degree of structural disease progression, is indicative of

348

continued therapeutic effectiveness.

AC C

EP

TE

D

349

16

ACCEPTED MANUSCRIPT

Acknowledgements

351

This study was funded by Eisai Inc. Editorial assistance was provided by Oxford PharmaGenesis

352

Inc. and was funded by Eisai Inc.

353

Author Disclosure Statement

354

RMT has served as a paid consultant for Eisai and Bayer.

355

MB has served as a paid consultant for Eisai and Bayer.

356

EG has served as a paid consultant for Eisai and Bayer.

357

SWK has served as a paid consultant for Eisai and Bayer.

358

MT has received grants and research support from Eisai, MSD, Boehringer Ingelheim,

359

AstraZeneca, Ono, Novartis, Bayer, NanoCarrier, Pfizer and has served as paid consultant for

360

Merck Serono, MSD, BMS, Bayer, Eisai, Otsuka, Astra Zeneca and Pfizer

361

MS Nothing to disclose

362

Address correspondence to:

363

R Michael Tuttle, MD

364

Endocrinology Service, Department of Medicine

365

Memorial Sloan Kettering Cancer Center

366

1275 York Avenue, New York, NY, USA 10021

367

Email: [email protected]

AC C

EP

TE

D

M AN U

SC

RI PT

350

368 369

References

370 371 372 373

1.

Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new american thyroid association staging system. Thyroid 2010; 20: 1341-9.

17

ACCEPTED MANUSCRIPT

2.

RI PT

3.

4.

SC

5.

*6.

M AN U

7.

8.

9.

D

10.

TE

11.

EP

12.

13. 14. 15. 16.

*17. *18. 19.

Vaisman F, Momesso D, Bulzico D, et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol (Oxf) 2012; 77: 132-138. Vaisman F, Tala H, Grewal R, et al. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. Thyroid 2011; 21: 1317-22. Haugen BR and Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev 2013; 34: 439-55. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91: 2892-9. Sabra M, Ghossein R, and Tuttle M. Time course and predictors of structural disease progression in pulmonary metastases arising from follicular cell derived thyroid cancer. Thyroid 2015: In press. Sabra MM, Dominguez JM, Grewal RK, et al. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab 2013; 98: E829-36. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer 1998; 83: 2638-48. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006; 16: 1229-42. Henriques de Figueiredo B, Godbert Y, Soubeyran I, et al. Brain metastases from thyroid carcinoma: a retrospective study of 21 patients. Thyroid 2014; 24: 270-6. Sherman SI. Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am 2008; 37: 511-24, xi. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014; 384: 319-28. Marotta V, Sciammarella C, Vitale M, et al. The evolving field of kinase inhibitors in thyroid cancer. Crit Rev Oncol Hematol 2015; 93: 60-73. Schlumberger M and Leboulleux S. Treatment of distant metastases from follicular cellderived thyroid cancer. F1000Prime Rep 2015; 7: 22. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodinerefractory thyroid cancer. N Engl J Med 2015; 372: 621-30. Carty SE, Doherty GM, Inabnet WB, 3rd, et al. American Thyroid Association statement on the essential elements of interdisciplinary communication of perioperative information for patients undergoing thyroid cancer surgery. Thyroid 2012; 22: 395-9. Collins VP, Loeffler RK, and Tivey H. Observations on growth rates of human tumors. Am J Roentgenol Radium Ther Nucl Med 1956; 76: 988-1000. Friberg S and Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol 1997; 65: 284-97. Norton L, Simon R, Brereton HD, et al. Predicting the course of Gompertzian growth. Nature 1976; 264: 542-5.

AC C

374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417

18

ACCEPTED MANUSCRIPT

22.

23.

27.

D

26.

TE

25.

M AN U

*24.

SC

RI PT

21.

Barbet J, Campion L, Kraeber-Bodere F, et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005; 90: 6077-84. Miyauchi A, Kudo T, Miya A, et al. Prognostic impact of serum thyroglobulin doublingtime under TSH suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid 2011; 7: 707-716. Miyauchi A, Onishi T, Morimoto S, et al. Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg 1984; 199: 461-6. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 2009; 69: 4885-93. Sabra M, Sherman E, and Tuttle M. Tumor volume doubling time of the pulmonary metastases predicts overall survival and can guide the initiation of multi-kinase inhibitor therapy in metastatic follicular cell derived thyroid carcinoma. Cancer 2017; Apr 3. doi: 10.1002/cncr.30690. [Epub ahead of print]. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26: 1-133. Schlumberger M, Brose M, Elisei R, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 2014; 2: 3568. Network NCC. NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma version 1.2016. 2016 [cited 2016 November 12].

EP

443

20.

AC C

418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442

19

ACCEPTED MANUSCRIPT

444

TABLES TABLE 1. CUMULATIVE PERCENTAGE OF PATIENTS DEMONSTRATING DISEASE

446

PROGRESSION OVER TIME

447

RAI avid disease

RAI refractory disease

1

17

12

29

2

35

5

55

10

65

RAI, radioactive iodine.

448

452 453 454 455

41

83

53

91

TE EP

451

53

AC C

450

26

D

449

SC

Entire cohort

M AN U

Year, %

RI PT

445

456 457

20

RI PT

TABLE 2. RELATIONSHIP BETWEEN PERCENTAGE INCREASE IN LARGEST TUMOR DIAMETER AND

459

CORRESPONDING DIAMETER DOUBLING TIME

M AN US C

458

Increase in largest tumor diameter per year, %

Size of metastatic focus, cm

Corresponding diameter doubling time, years

(1 cm in diameter at baseline)

20% 30% 40%

D

50%

461 462 463 464

1.3

2.7

1.4

2.1

1.5

1.7

1.8

1.2

2.0

1.0

AC C

460

3.8

EP

100%

TE

75%

1.2

21

RI PT

TABLE 3. DIAMETER DOUBLING TIMES AND TUMOR DIAMETERS THAT SHOULD PROMPT CONSIDERATION FOR

466

MULTITARGETED KINASE INHIBITOR THERAPY Diameter doubling time, years

M AN US C

465

Corresponding increase in

Diameter of metastatic focus that should

maximum diameter per year, %

prompt consideration for initiation of

Corresponding tumor volume, mL

multitargeted kinase inhibitor therapy, cm

469 470 471 472

40–100

2–4

20–40

>4

< 20

0.5

1.0–1.5

0.5–1.8

1.5–2.0

1.8–4.2

Usually not indicated

-

TE

D

1–2

≈ 1.0

EP

468

100

AC C

467

<1

22

ACCEPTED MANUSCRIPT

FIGURE TITLES AND LEGENDS

474

FIG 1. Overall survival and progression-free survival in a cohort of 199 patients with pulmonary

475

metastases from nonanaplastic follicular cell-derived thyroid cancer.

476

CI, confidence interval.

RI PT

473

SC

477

FIG 2. Theoretical growth curves representing the most common patterns observed in clinical

479

practice in patients with metastatic disease that continues to be RAI responsive or becomes RAI

480

refractory.

481

RAI, radioactive iodine.

M AN U

478

D

482

FIG 3. Relationship between tumor diameter and tumor volume demonstrating dramatic

484

increases in tumor volume, with relatively small changes in tumor diameter.

487 488 489

EP

486

AC C

485

TE

483

490 491 492

23

ACCEPTED MANUSCRIPT

FIG 4. Growth curves for a tumor growing from 0.5 to 8 cm in maximal diameter with a

494

doubling time of 6 months, 1 year, 2 years, and 4 years plotted as (A) the diameter of the lesion

495

versus time or (B) the log of the lesion diameter versus time (semilog).

496

The inflection point (indicated by the grey triangle in panel B) is critical point in time when the

497

volume and rate of progression of metastatic structural disease merits consideration for initiation

498

of systemic therapy.

SC

RI PT

493

M AN U

499 500

FIG 5. Therapeutic decision-making in metastatic thyroid cancer.

501

RAI, radioactive iodine.

502

AC C

EP

TE

D

503

24

ED

PT M AN

ED M

ED

M

EP TE D

M AN U

CE ED

PT

M AN US